Insider Transactions in Q1 2023 at Sensei Biotherapeutics, Inc. (SNSE)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 23
2023
|
Apeiron Investment Group Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,200
+0.04%
|
$2,200
$1.61 P/Share
|
|
Feb 15
2023
|
Patrick Stephen Gallagher Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,383
-21.56%
|
$9,383
$1.5 P/Share
|
|
Feb 15
2023
|
Erin Colgan CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,943
-13.85%
|
$10,943
$1.5 P/Share
|
|
Feb 15
2023
|
John Celebi PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,492
-15.61%
|
$20,492
$1.5 P/Share
|
|
Feb 15
2023
|
Horst Edward Van Der CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,525
-15.26%
|
$9,525
$1.5 P/Share
|
|
Feb 15
2023
|
John Celebi PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
73,193
+23.6%
|
-
|
|
Feb 15
2023
|
Erin Colgan CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
51,346
+29.66%
|
-
|
|
Feb 15
2023
|
Patrick Stephen Gallagher Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,513
+37.3%
|
-
|
|
Feb 15
2023
|
Horst Edward Van Der CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
41,265
+28.29%
|
-
|